Latest Headlines

  1. SIRION Biotech Licenses Technology To National Institute Of Allergy And Infectious Diseases To Boost Clinical Efficacy Of Lentivector Gene Therapy For X-Linked SCID

    SIRION Biotech GmbH (“SIRION”) recently announced the entry into a license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, a leading clinical research institute in the gene therapy space, pursuant to which NIAID has licensed SIRION’s LentiBOOST technology to improve clinical efficacy of its hematopoietic stem cell gene therapy programs.

  2. Aldevron To Build 14-Acre Gene Therapy Manufacturing Campus

    Aldevron, a leader in the production of plasmid DNA, proteins, mRNA and antibodies; announced today expansion plans for a 14-acre campus at its headquarters in Fargo, N.D. Phase one construction will begin in August. Upon completion of the campus, the annual capacity will exceed $1 Billion of plasmid DNA, RNA, gene editing enzymes, and other biologics.

  3. Iovance Biotherapeutics Announces New Manufacturing Facility Plans For Cell Therapy Production

    Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement to build an approximately 136,000 square foot commercial-scale production facility in Philadelphia for commercial and clinical production of autologous TIL products, including its candidate lifileucel.

  4. GE Healthcare And World Courier Collaborate To Drive Commercialization Of Cell And Gene Therapies

    GE Healthcare and World Courier, a part of AmerisourceBergen, are combining their expertise in manufacturing and logistics to better patient access to cell and gene therapies. Together, they aim to create a seamless end-to-end supply chain that will enable the developers of these treatments to meet increasing global demand.

  5. Kite Announces Plans For New State-Of-The-Art Facility To Expand Cell Therapy Production Capabilities

    Kite, a Gilead Company, recently announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer.

  6. Helga Salling Traore Joins IPS As Regional Director, Southeastern US

    IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management and validation (EPCMV) services, is pleased to announce the appointment of Ms. Helga Salling Traore to the position of Regional Director, Southeastern United States.

  7. Catalent To Acquire Gene Therapy Leader Paragon Bioservices, Inc. For $1.2B

    Catalent, Inc., the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2B.

  8. GenCure Selects G-CON Manufacturing PODs For New Biomanufacturing Facility

    GenCure has selected G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, for its new multi-product cell therapy facility

  9. G-CON Expands Into Europe With The Formation Of G-CON Manufacturing Europe Ltd

    G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, announced today that it has formed a new entity in Ireland, G-CON Manufacturing Europe Ltd.

  10. Bluebird Bio Opens New Gene Therapy Manufacturing Facility In North Carolina

    A gene therapy company that develops treatments for devastating diseases, bluebird bio Inc. opened its 125,000-square-foot manufacturing facility in Durham, North Carolina.